Symposia: Lymphomas: Translational—Molecular and Genetic
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Hodgkin lymphoma, adult, Lymphomas, Translational Research, non-Hodgkin lymphoma, elderly, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, Clinical Research, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, Technology and Procedures, molecular biology, Study Population, Human, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Biological therapies, Antibody Therapy, Hodgkin lymphoma, adult, Lymphomas, Translational Research, non-Hodgkin lymphoma, elderly, genomics, bioinformatics, Chimeric Antigen Receptor (CAR)-T Cell Therapies, B Cell lymphoma, Combination therapy, Clinical Research, Diseases, indolent lymphoma, Therapies, Immunotherapy, aggressive lymphoma, Lymphoid Malignancies, Biological Processes, Technology and Procedures, molecular biology, Study Population, Human, Minimal Residual Disease , machine learning, molecular testing, omics technologies
Sunday, December 11, 2022: 12:00 PM-1:30 PM
Great Hall BC
(Ernest N. Morial Convention Center)
Moderators:
David W. Scott, PhD, MD, FRACP, FRCPA, British Columbia Cancer Agency
and
Lisa Giulino Roth, MD, Weill Cornell Medical College
Disclosures:
Scott: Abbvie: Consultancy; AstraZeneca: Consultancy, Honoraria; Incyte: Consultancy; Janssen: Consultancy, Research Funding; Roche: Research Funding; NanoString: Patents & Royalties.
12:00 PM
12:15 PM
12:30 PM
12:45 PM
1:00 PM
1:15 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH